Eisai's Fycompa falls at German HTA comparator hurdle, like GSK's Trobalt
This article was originally published in Scrip
Executive Summary
Comparator issues that proved troublesome for GlaxoSmithKline's antiepileptic Trobalt (retigabine) in Germany are now causing problems for Eisai's own antiepileptic Fycompa (perampanel). IQWiG, the body that carries out the preliminary scientific assessment for Germany's AMNOG early benefit assessments, said that Eisai's drug offers no additional benefit over comparators because it did not submit any relevant data lamotrigine or topiramate.